通过综合生物信息学分析和机器学习来探索阿尔茨海默氏症中与衰老相关的基因对抗的Gastrodin
Lipeng Zhou1, Xinying Chen1, Shuang Liang1
1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
International journal of molecular sciences
|September 27, 2025
概括
加斯特罗丁是一种来自Gastrodia elata的化合物,在阿尔茨海默氏病 (AD) 中表现出神经保护作用. 这项研究确定SNAP25是AD中关键的与衰老相关的基因,通过向该基因揭示了gastrodin的潜在治疗机制.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 遗传学和生物信息学
背景情况:
- 加斯特罗丁 (Gastrodin) 来自Gastrodia elata Blume,具有显著的神经保护性质,特别适用于阿尔茨海默病 (AD).
- 老龄化是阿尔茨海默氏症的主要风险因素,但将加斯托丁的作用与阿尔茨海默氏症中与老龄化相关的基因联系起来的分子机制在很大程度上仍未被探索.
研究的目的:
- 在阿尔茨海默病的背景下,阐明胃素在调节与衰老相关的基因中的分子机制.
- 为了确定关键的与衰老相关的基因和潜在的治疗点在AD治疗中.
主要方法:
- 利用基因表达数据集 (GEO) 和权重基因共同表达网络分析 (WGCNA) 来识别AD,关键AD模块和衰老基因中差异表达基因 (DEGs) 之间的重叠基因.
- 进行了基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 路径分析,构建了蛋白质-蛋白质相互作用 (PPI) 网络,并应用了机器学习算法 (随机森林,LASSO,SVM,Boruta) 来识别枢纽基因.
- 进行了分子对接和分子动力学模拟,以评估 gastrodin 与已确定核心目标的结合亲和力.
主要成果:
- 确定了29个交叉基因和随后的9个常见的枢纽基因,其中4个基因 (GFAP,NPY,SNAP25,SST) 被突出显示为AD中潜在的枢纽衰老相关基因.
- 观察到显著差异表达:GFAP是上调的,而NPY,SNAP25和SST是下调的 (p <0.05).
- 分子对接和模拟揭示了加斯托丁和SNAP25之间强烈的结合亲和力.
结论:
- SNAP25被确定为关键的与老化相关的基因,与阿尔茨海默病有关.
- 加斯特罗丁通过向特定的基因,特别是SNAP25和相关的信号通路来证明AD的治疗潜力.
- 这些发现为阿尔茨海默病管理中胃素的临床应用提供了宝贵的见解.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.3K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
